NCT05321407View on ClinicalTrials.gov

COVID-19 Vaccine Responses in PIDD Subjects

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
X-linked AgammaglobulinemiaXLAPrimary Immune DeficiencyCVIDCommon Variable ImmunodeficiencyPrimary Antibody DeficienciesSecondary Hypogammaglobulinemia
Trial Locations (3)

27599

University of North Carolina, Chapel Hill, Chapel Hill

27708

Duke University, Durham

33701

University of South Florida, St. Petersburg

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Jeffrey Modell Foundation

UNKNOWN

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

University of South Florida

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Duke University

OTHER

NCT05321407 - COVID-19 Vaccine Responses in PIDD Subjects | Biotech Hunter | Biotech Hunter